StreetInsider.com News Articles

Form 4 Medpace Holdings, Inc. For: Oct 21 Filed by: BURWIG SUSAN E

Fri, 23 Oct 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20261023/27227979.html

Medpace (MEDP) PT Raised to $700 at UBS

Fri, 23 Oct 2026 09:34:35 -0400

UBS analyst Kevin Caliendo raised the price target on Medpace (NASDAQ: MEDP) to $700.00 (from $673.00) while maintaining a Neutral rating.

Medpace (MEDP) PT Raised to $673 at TD Cowen

Fri, 23 Oct 2026 08:56:39 -0400

TD Cowen analyst Charles Rhyee raised the price target on Medpace (NASDAQ: MEDP) to $673.00 (from $492.00) while maintaining a Hold rating.

Medpace (MEDP) PT Raised to $633 at Truist Securities

Fri, 23 Oct 2026 07:21:44 -0400

Truist Securities analyst Jailendra Singh raised the price target on Medpace (NASDAQ: MEDP) to $633.00 (from $609.00) while maintaining a Hold rating.

Medpace (MEDP) PT Raised to $730 at Mizuho

Fri, 23 Oct 2026 06:57:40 -0400

Mizuho analyst Ann Hynes raised the price target on Medpace (NASDAQ: MEDP) to $730.00 (from $700.00) while maintaining a Outperform rating.

Medpace (MEDP) PT Raised to $699 at Baird

Fri, 23 Oct 2026 06:45:08 -0400

Baird analyst Eric Coldwell raised the price target on Medpace (NASDAQ: MEDP) to $699.00 (from $638.00) while maintaining a Neutral rating.

Medpace (MEDP) PT Raised to $675 at Barclays

Fri, 23 Oct 2026 04:25:23 -0400

Barclays analyst Luke Sergott raised the price target on Medpace (NASDAQ: MEDP) to $675.00 (from $625.00) while maintaining a Equalweight rating.

Form 10-Q Medpace Holdings, Inc. For: Sep 30

Thu, 22 Oct 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20261022/27222497.html

Medpace beats Q3 estimates but guides below on revenue

Wed, 21 Oct 2026 17:25:05 -0400

Investing.com -- Medpace Holdings Inc (NASDAQ:MEDP) reported third quarter results that exceeded analyst expectations, but shares slipped 1.9% in after-hours trading Wednesday as the company's full-year revenue guidance disappointed investors.

The clinical contract research organization posted adjusted earnings of $4.84 per share for the third quarter, beating the analyst consensus of $4.44 by $0.40. Revenue reached $716.0 million, slightly above the estimate of $714.47 million and up 8.5% from $659.9 million in the prior-year period. The company reported EBITDA of $172.1 million, representing a 24.0% margin and a 16.0% increase YoY.

For full-year 2026, Medpace issued guidance of $2.835

Medpace beats Q3 estimates but guides below on revenue

Wed, 21 Oct 2026 17:25:05 -0400

For full-year 2026, Medpace issued guidance of $2.835

Medpace Holdings (MEDP) Tops Q3 EPS by 40c; offers guidance

Wed, 21 Oct 2026 16:27:12 -0400

Medpace Holdings (NASDAQ: MEDP) reported Q3 EPS of $4.84, $0.40 better than the analyst estimate of $4.44. Revenue for the quarter came in at $716 million versus the consensus estimate of $714.47 million.

GUIDANCE:

Medpace Holdings sees FY2026 EPS of $17.97-$18.32, versus the consensus of $17.72. Medpace Holdings sees FY2026 revenue of $2.835-2.855 billion, versus the consensus of $2.852 billion.

For earnings history and earnings-related data on Medpace Holdings (MEDP) click here.

Medpace Holdings (MEDP) Tops Q3 EPS by 40c; offers guidance

Wed, 21 Oct 2026 16:27:12 -0400

GUIDANCE:

Medpace Holdings sees FY2026 EPS of $17.97-$18.32, versus the consensus of $17.72. Medpace Holdings sees FY2026 revenue of $2.835-2.855 billion, versus the consensus of $2.852 billion.

For earnings history and earnings-related data on Medpace Holdings (MEDP) click here.

Medpace Holdings, Inc. Reports Third Quarter 2026 Results

Wed, 21 Oct 2026 16:15:00 -0400

Revenue of $716.0 million in the third quarter of 2026 increased 8.5% from revenue of $659.9 million for the comparable prior-year period, representing a backlog conversion rate of 23.8%.
Net new business awards were $873.4 million in the third quarter of 2026, representing an increase of 10.6% from net new business awards of $789.6 million for the comparable prior-year period.
Third quarter of 2026 GAAP net income was $137.5 million, or $4.84 per diluted share, versus GAAP net income of $111.1 million, or $3.86 per diluted share, for the comparable prior-year period. Net income margin was 19.2% and 16.8% for the

Medpace Holdings, Inc. Reports Third Quarter 2026 Results

Wed, 21 Oct 2026 16:15:00 -0400

Revenue of $716.0 million in the third quarter of 2026 increased 8.5% from revenue of $659.9 million for the comparable prior-year period, representing a backlog conversion rate of 23.8%.

Net new business awards were $873.4 million in the third quarter of 2026, representing an increase of 10.6% from net new business awards of $789.6 million for the comparable prior-year period.

Third quarter of 2026 GAAP net income was $137.5 million, or $4.84 per diluted share, versus GAAP net income of $111.1 million, or $3.86 per diluted share, for the comparable prior-year period. Net income margin was 19.2% and 16.8% for the

Form 8-K Medpace Holdings, Inc. For: Oct 20

Wed, 21 Oct 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20261021/27216635.html

Form 4 Medpace Holdings, Inc. For: Oct 12 Filed by: BURWIG SUSAN E

Wed, 14 Oct 2026 16:14:00 -0400
si-local-file:///var/storage/secattach/20261014/27187254.html

Form 4 Medpace Holdings, Inc. For: Oct 07 Filed by: BURWIG SUSAN E

Fri, 09 Oct 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20261009/27171683.html

Medpace (MEDP) PT Raised to $700 at Mizuho

Wed, 07 Oct 2026 06:44:47 -0400
Mizuho analyst Ann Hynes raised the price target on Medpace (NASDAQ: MEDP) to $700.00 (from $665.00) while maintaining a Outperform rating.

Medpace (MEDP) PT Raised to $625 at Barclays

Wed, 07 Oct 2026 03:50:47 -0400
Barclays analyst Luke Sergott raised the price target on Medpace (NASDAQ: MEDP) to $625.00 (from $600.00) while maintaining a Equalweight rating.

Form 4 Medpace Holdings, Inc. For: Sep 30 Filed by: McCarthy Cornelius P. III

Fri, 02 Oct 2026 17:19:00 -0400
si-local-file:///var/storage/secattach/20261002/27143590.html

Form 4 Medpace Holdings, Inc. For: Sep 30 Filed by: Kraft Robert O.

Fri, 02 Oct 2026 17:15:00 -0400
si-local-file:///var/storage/secattach/20261002/27143528.html

Form 4 Medpace Holdings, Inc. For: Sep 30 Filed by: Carley Brian T

Fri, 02 Oct 2026 17:12:00 -0400
si-local-file:///var/storage/secattach/20261002/27143489.html

Form 4 Medpace Holdings, Inc. For: Sep 29 Filed by: Troendle August J.

Thu, 01 Oct 2026 17:43:00 -0400
si-local-file:///var/storage/secattach/20261001/27137427.html

UBS Resumes Medpace (MEDP) at Neutral

Wed, 30 Sep 2026 05:47:56 -0400

UBS analyst Kevin Caliendo resumes coverage on Medpace (NASDAQ: MEDP) with a Neutral rating and a price target of $673.00.
The analyst comments: “We assume coverage of MEDP at Neutral. We believe market expectations for revenue growth and margins are reasonable and valuation is highest in the CRO peer group limiting the potential for multiple upside. Strong 2Q26 results set the bar higher for bookings and earnings in 2H26, which we believe investors are expecting.
TTM biotech funding is up 87% y/y and is highly correlated to bookings, especially MEDP since the company derives 95% of its revenue from biotechs. Biotech R&D

UBS Resumes Medpace (MEDP) at Neutral

Wed, 30 Sep 2026 05:47:56 -0400

UBS analyst Kevin Caliendo resumes coverage on Medpace (NASDAQ: MEDP) with a Neutral rating and a price target of $673.00.
The analyst comments: “We assume coverage of MEDP at Neutral. We believe market expectations for revenue growth and margins are reasonable and valuation is highest in the CRO peer group limiting the potential for multiple upside. Strong 2Q26 results set the bar higher for bookings and earnings in 2H26, which we believe investors are expecting.
TTM biotech funding is up 87% y/y and is highly correlated to bookings, especially MEDP since the company derives 95% of its revenue from biotechs. Biotech R&D